Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00635024 · OUTCOME

Duration of Response (DOR)

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma · Source last updated 2017-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
up to 2 years

What was measured

DOR was calculated from the documentation of response (CR, VGPR or PR) until the date of progression in the subset of patients who responded.

Analysis population: All patients are non-evaluable - no patients responded to treatment.

Groups in this outcome

Anti-thymocyte Globulin/Melphalan

Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Anti-thymocyte Globulin/Melphalan0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
DOR was calculated from the documentation of response (CR, VGPR or PR) until the date of progression in the subset of patients who responded.
groups
  1. description
    Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)
    id
    OG000
    title
    Anti-thymocyte Globulin/Melphalan
population Description
All patients are non-evaluable - no patients responded to treatment.
reporting Status
POSTED
time Frame
up to 2 years
title
Duration of Response (DOR)
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice